367 related articles for article (PubMed ID: 28195880)
1. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
[TBL] [Abstract][Full Text] [Related]
2. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
3. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
4. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Dill EA; Dillon PM; Bullock TN; Mills AM
Mod Pathol; 2018 Oct; 31(10):1513-1522. PubMed ID: 29802358
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
7. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
Stovgaard ES; Bokharaey M; List-Jensen K; Roslind A; Kümler I; Høgdall E; Nielsen D; Balslev E
Breast Cancer Res Treat; 2020 Jun; 181(3):553-560. PubMed ID: 32358635
[TBL] [Abstract][Full Text] [Related]
11. [Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
Wang XR; Zhang NN; Lyu F; Wang HL; Liu YP
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):430-434. PubMed ID: 32392925
[No Abstract] [Full Text] [Related]
12. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Li F; Ren Y; Wang Z
J Cancer Res Ther; 2018 Jan; 14(1):150-154. PubMed ID: 29516978
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Cimino-Mathews A; Thompson E; Taube JM; Ye X; Lu Y; Meeker A; Xu H; Sharma R; Lecksell K; Cornish TC; Cuka N; Argani P; Emens LA
Hum Pathol; 2016 Jan; 47(1):52-63. PubMed ID: 26527522
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
Gottlieb CE; Mills AM; Cross JV; Ring KL
Gynecol Oncol; 2017 Mar; 144(3):607-612. PubMed ID: 28065619
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
Tawfik O; Kimler BF; Karnik T; Shehata P
Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
18. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
Muenst S; Schaerli AR; Gao F; Däster S; Trella E; Droeser RA; Muraro MG; Zajac P; Zanetti R; Gillanders WE; Weber WP; Soysal SD
Breast Cancer Res Treat; 2014 Jul; 146(1):15-24. PubMed ID: 24842267
[TBL] [Abstract][Full Text] [Related]
19. Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition.
Kwon MJ; Rho YS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Kim ES; Park B; Hong M; Min KW
Hum Pathol; 2018 Oct; 80():28-39. PubMed ID: 29634978
[TBL] [Abstract][Full Text] [Related]
20. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.
He J; Huo L; Ma J; Zhao J; Bassett RL; Sun X; Ueno NT; Lim B; Gong Y
Am J Clin Pathol; 2018 Feb; 149(3):253-261. PubMed ID: 29425258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
